<DOC>
	<DOCNO>NCT00726830</DOCNO>
	<brief_summary>RATIONALE : Methadone , morphine , oxycodone may help relieve pain caused cancer . It yet know whether methadone effective morphine oxycodone treat pain patient cancer . PURPOSE : This randomized clinical trial study methadone see well work compare morphine oxycodone treat pain patient cancer .</brief_summary>
	<brief_title>Methadone , Morphine , Oxycodone Treating Pain Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare effectiveness opioid rotation oral methadone versus opioid rotation another long-acting strong opioid ( sustained-release morphine oxycodone ) control pain ( i.e. , analgesia ) patient cancer . Secondary - To compare tolerability opioid rotation oral methadone versus opioid rotation another long-acting strong opioid ( sustained-release morphine oxycodone ) . - To identify subset patient likely benefit opioid rotation oral methadone , term significant improvement pain control opioid tolerability . OUTLINE : This multicenter study . Patients stratify accord baseline opioid ( morphine v oxycodone ) . Patients randomize 1 2 treatment arm . - Arm I : Patients switch current opioid medication ( oxycodone morphine ) methadone . Patients receive oral methadone 2-3 time daily 4 week . - Arm II : Patients currently receive oxycodone switch sustained-release ( SR ) morphine . Patients currently receive morphine switch SR oxycodone . Patients receive either oral SR morphine oxycodone 2-3 time daily 4 week . Patients assess pain control complete symptom questionnaire day 1 , 8 , 15 , 22 , 28 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<mesh_term>Methadone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Receiving ongoing care outpatient medical oncology set Selfreported pain ( cause ) longacting strong opioids ( morphine oxycodone ) prescribe administered Oral morphineequivalent daily dose ( MEDD ) exist opioid regimen ( longacting immediaterelease ) 40300 mg/day Worst pain score scale 0 ( pain ) 10 ( bad pain ) ≥ 5 ≥ 1 week duration base verbal selfreport AND/OR ≥ 1 persistently bothersome symptom attribute opioid side effect ( e.g. , fatigue , confusion , depress level consciousness , memory loss , personality change , anorexia , constipation , dehydration , nausea , vomit , weight loss , pruritus , urticaria , impotence , reduce libido , urinary retention hesitancy ) PATIENT CHARACTERISTICS : None follow condition could predispose patient prolong QT intervalassociated tachycardia : Serum potassium &lt; 3.0 mg/dL Cocaine abuse within past 3 month Family history sudden death Advanced heart failure ( ejection fraction &lt; 40 % and/or New York Heart Association ( NYHA ) class III IV heart disease ) No know suspect cognitive impairment could interfere adherence medication plan selfreport symptom side effect Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics More 4 week since prior radiotherapy surgery local control cancer pain palliation More 60 day since prior use longacting opioid ( i.e. , new longacting opioid ) patient switch study More 12 week since prior methadone therapy More 3 day since prior concurrent transdermal fentanyl , oxymorphone , buprenorphine Concurrent systemic anticancer therapy bisphosphonates allow provided therapy initiate ≥ 4 week ago Concurrent tricyclic antidepressant , Nonsteroidal Antiinflammatory Drugs ( NSAIDs ) , anticonvulsant , adjuvant analgesic psychostimulants allow provided therapy initiate ≥ 2 week ago Dose expect remain stable first week opioid rotation study No concurrent methadone maintenance therapy opioid addiction No concurrent intrathecal infusion analgesic No concurrent antiarrhythmic medication ( e.g. , amiodarone quinidine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>mast cell leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>AIDS-related diffuse large cell lymphoma</keyword>
	<keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
	<keyword>AIDS-related diffuse small cleave cell lymphoma</keyword>
	<keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>AIDS-related small noncleaved cell lymphoma</keyword>
	<keyword>AIDS-related lymphoblastic lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>primary central nervous system Hodgkin lymphoma</keyword>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
</DOC>